These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26714423)

  • 21. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. ex vivo evaluation and pharmacodynamic study.
    Singh J; Chhabra G; Pathak K
    Drug Dev Ind Pharm; 2014 Sep; 40(9):1223-32. PubMed ID: 23837522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancing effects of fatty acids on piroxicam permeation through rat skins.
    Shin SC; Shin EY; Cho CW
    Drug Dev Ind Pharm; 2000 May; 26(5):563-6. PubMed ID: 10789070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug release into hydrogel-based subcutaneous surrogates studied by UV imaging.
    Ye F; Larsen SW; Yaghmur A; Jensen H; Larsen C; Ostergaard J
    J Pharm Biomed Anal; 2012 Dec; 71():27-34. PubMed ID: 22889608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delivery of atovaquone and proguanil across sublingual membranes, in vitro.
    Wallace E; Ong CM; Heard CM
    Pharm Dev Technol; 2012; 17(6):770-6. PubMed ID: 21612571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [In vitro evaluation of the gels properties prepared thermosensitive polymers as vehicles for administration substance by injection].
    Karolewicz B; Owczarek A; Pluta J
    Polim Med; 2011; 41(4):3-15. PubMed ID: 22332321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro release studies of piroxicam from oil-in-water creams and hydroalcoholic gel topical formulations.
    Rafiee-Tehrani M; Mehramizi A
    Drug Dev Ind Pharm; 2000 Apr; 26(4):409-14. PubMed ID: 10769782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of hydroxy propyl guar derivative for its gelling property and it's use in the formulation of tenoxicam gels.
    Swamy NG; Dharmarajan TS; Paranjothi KL
    Pak J Pharm Sci; 2007 Jan; 20(1):61-6. PubMed ID: 17337431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biodegradable thermogels.
    Park MH; Joo MK; Choi BG; Jeong B
    Acc Chem Res; 2012 Mar; 45(3):424-33. PubMed ID: 21992012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of non-ionic surfactants as permeation enhancers towards piroxicam from the poloxamer gel through rat skins.
    Shin SC; Cho CW; Oh IJ
    Int J Pharm; 2001 Jul; 222(2):199-203. PubMed ID: 11427350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation.
    Bachhav YG; Patravale VB
    Acta Pharm; 2010 Jun; 60(2):153-63. PubMed ID: 21134852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of cellulose derivative and ethylene glycol on optimization of lornoxicam transdermal formulation.
    Shahzad Y; Khan Q; Hussain T; Shah SN
    Int J Biol Macromol; 2013 Oct; 61():26-32. PubMed ID: 23827761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
    Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
    Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Piroxicam bioadhesive ocular inserts: physicochemical characterization and evaluation in prostaglandin-induced inflammation.
    Gilhotra RM; Gilhotra N; Mishra DN
    Curr Eye Res; 2009 Dec; 34(12):1065-73. PubMed ID: 19958126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poloxamer 407 microspheres for orotransmucosal drug delivery. Part II: In vitro/in vivo evaluation.
    Monti D; Burgalassi S; Rossato MS; Albertini B; Passerini N; Rodriguez L; Chetoni P
    Int J Pharm; 2010 Nov; 400(1-2):32-6. PubMed ID: 20728514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transbuccal permeation, anti-inflammatory activity and clinical efficacy of piroxicam formulated in different gels.
    Attia MA; El-Gibaly I; Shaltout SE; Fetih GN
    Int J Pharm; 2004 May; 276(1-2):11-28. PubMed ID: 15113610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
    Prabhu S; Ortega M; Ma C
    Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
    Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
    Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo evaluation of cubosomal in situ nasal gel containing resveratrol for brain targeting.
    Ahirrao M; Shrotriya S
    Drug Dev Ind Pharm; 2017 Oct; 43(10):1686-1693. PubMed ID: 28574732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poloxamer 407 microspheres for orotransmucosal drug delivery. Part I: formulation, manufacturing and characterization.
    Albertini B; Passerini N; Di Sabatino M; Monti D; Burgalassi S; Chetoni P; Rodriguez L
    Int J Pharm; 2010 Oct; 399(1-2):71-9. PubMed ID: 20696227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carboxymethyl mungbean starch as a new pharmaceutical gelling agent for topical preparation.
    Kittipongpatana OS; Burapadaja S; Kittipongpatana N
    Drug Dev Ind Pharm; 2009 Jan; 35(1):34-42. PubMed ID: 18720150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.